ArticleBMC veterinary research2006
In vitro comparison of antiviral drugs against feline herpesvirus 1.
Article in BMC veterinary research, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 44 citations in OpenAlex.
- In vitro antiviral efficacy of amenamevir against feline herpesvirus 1.The Journal of veterinary medical science · 2025Article
- Development of a reporter feline herpesvirus-1 for antiviral screening assays.Veterinary research · 2024Article
- Saikosaponin B2, Punicalin, and Punicalagin in Vitro Block Cellular Entry of Feline Herpesvirus-1.Viruses · 2024Article
- Antiviral Activity of Nitazoxanide and Miltefosine Against FeHV-1 In Vitro.Veterinary medicine international · 2024Article
- Article
- Comparative Efficacy of Topical Ophthalmic Ganciclovir and Oral Famciclovir in Cats with Experimental Ocular Feline Herpesvirus-1 Epithelial Infection.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2022Article
- Assessment of Cidofovir for Treatment of Ocular Bovine Herpesvirus-1 Infection in Cattle Using an Ex-Vivo Model.Viruses · 2021Article
- In vitro efficacy of ganciclovir against feline herpesvirus type 1 and assessment of ocular tolerability in healthy cats.Journal of feline medicine and surgery · 2021Article
- Antiviral effect of sinefungin on in vitro growth of feline herpesvirus type 1.The Journal of antibiotics · 2019Article
- Review
- A review of antiviral drugs and other compounds with activity against feline herpesvirus type 1.Veterinary ophthalmology · 2016Review
- Ocular manifestations of feline viral diseases.Veterinary journal (London, England : 1997) · 2014Review
- ABCD: Update of the 2009 guidelines on prevention and management of feline infectious diseases.Journal of feline medicine and surgery · 2013Article
- Treatment of corneal ulcers: what are the medical options?Journal of feline medicine and surgery · 2010Review
- Feline herpesvirus infection. ABCD guidelines on prevention and management.Journal of feline medicine and surgery · 2009Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFeline herpesvirus 1 (FHV-1) is a common cause of respiratory and ocular disease in cats. Especially in young kittens that have not yet reached the age of vaccination, but already lost maternal immunity, severe disease may occur. Therefore, there is a need for an effective antiviral treatment. In the present study, the efficacy of six antiviral drugs, i.e. acyclovir, ganciclovir, cidofovir, foscarnet, adefovir and 9-(2-phosphonylmethoxyethyl)-2, 6-diaminopurine (PMEDAP), against FHV-1 was compared in Crandell-Rees feline kidney (CRFK) cells using reduction in plaque number and plaque size as parameters.
resultsThe capacity to reduce the number of plaques was most pronounced for ganciclovir, PMEDAP and cidofovir. IC50 (NUMBER) values were 3.2 microg/ml (12.5 microM), 4.8 microg/ml (14.3 microM) and 6 microg/ml (21.5 microM), respectively. Adefovir and foscarnet were intermediately efficient with an IC50 (NUMBER) of 20 microg/ml (73.2 microM) and 27 microg/ml (140.6 microM), respectively. Acyclovir was least efficient (IC50 (NUMBER) of 56 microg/ml or 248.7 microM). All antiviral drugs were able to significantly reduce plaque size when compared with the untreated control. As observed for the reduction in plaque number, ganciclovir, PMEDAP and cidofovir were most potent in reducing plaque size. IC50 (SIZE) values were 0.4 microg/ml (1.7 microM), 0.9 microg/ml (2.7 microM) and 0.2 microg/ml (0.7 microM), respectively. Adefovir and foscarnet were intermediately potent, with an IC50 (SIZE) of 4 microg/ml (14.6 microM) and 7 microg/ml (36.4 microM), respectively. Acyclovir was least potent (IC50 (SIZE) of 15 microg/ml or 66.6 microM). The results demonstrate that the IC50 (SIZE) values were notably lower than the IC50 (NUMBER) values. The most remarkable effect was observed for cidofovir and ganciclovir. None of the products were toxic for CRFK cells at antiviral concentrations.
conclusionIn conclusion, measuring reduction in plaque number and plaque size are two valuable and complementary means of assessing the efficacy of an antiviral drug. By using these parameters for six selected antiviral drugs, we found that ganciclovir, PMEDAP, and cidofovir are the most potent inhibitors of FHV-1 replication in CRFK cells. Therefore, they may be valuable candidates for the treatment of FHV-1 infection in cats.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.